Top-News
Quelle: - pixabay.com:
Vasomedical to Report Third Quarter 2013 Results on November 14, 2013
WESTBURY, N.Y., Nov. 5, 2013 /PRNewswire/ -- Vasomedical, Inc. (OTC BB: VASO), announced today that it will release its financial results for the three months ended September 30, 2013 on Thursday, November 14, 2013.
The Company will host a conference call on Thursday, November 14th at 1:00 p.m. ET featuring remarks by Jun Ma, Ph.D., President and CEO of Vasomedical, and Michael Beecher, Chief Financial Officer of Vasomedical. To dial into the conference call, please dial 1-866-393-1344 from the U.S. or 1-631-291-4669, internationally. All dial-in participants must use the following code to access the call: 94523097. Please call at least five minutes before the scheduled start time. The conference call will also be available via webcast and can be accessed through the Investor Relations section of Vasomedical's website, www.vasomedical.com, and www.kcsa.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.
A replay of the conference call will be available approximately two hours after completion of the live conference call at www.vasomedical.com or www.kcsa.com. To access the dial-in replay of the call, which will be available until December 16, 2013, please dial 1-855-859-2056 or 1-404-537-3406. All dial-in participants must use the following code to access the call: 94523097.
About Vasomedical
Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, Vasomedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; Vasomedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
SOURCE Vasomedical, Inc.
Für dich aus unserer Redaktion zusammengestellt
Community-Beiträge zu Vasomedical Corp
12.11.2015 - 16:32 Uhr
Bergkämpfer zahlen, ok
Vasomedical Announces Third Quarter 2015 ResultsReporting 128% Revenue Growth and Operating Profit of $1.3 Million for the QuarterMarketwired Vasomedical, Inc.1 hour ago PLAINVIEW, NY--(Marketwired - Nov 12, 2015) - Vasomedical, Inc. ("Vasomedical") (OTC PINK: VASO) today reported its operating results for the three months ...
20.08.2015 - 08:39 Uhr
Bergkämpfer erst kommt alles anders
und erst später.....
“Dark Horse” definition: a medical device, biotech or pharmaceutical company, little-known but growing fast. Think “innovation” and amazing products, not “me-too” products. They need experienced B2B folks to get them to the next level — especially if you have contacts among their call points and new product launch experience. To ...
Jetzt anmelden und diskutieren
Registrieren
Login
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
